Conformational polymorphism in aripiprazole: Preparation, stability and structure of five modifications

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 2010-2026

  Braun, Doris E ^a   Gelbrich, Thomas ^a   Kahlenberg, Volker ^a   Tessadri, Richard ^a   Wieser, Josef ^b   Griesser, Ulrich J ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aripiprazole; Conformational polymorphism; Hirshfeld surfaces; IR spectroscopy; Raman spectroscopy; Single crystal structure; Thermal analysis; Thermodynamics; X ray diffractometry

Indexed keywords

ARIPIPRAZOLE; HYDROGEN; NITROGEN; OXYGEN; SOLVENT;

ARTICLE; CHEMICAL BOND; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONFORMATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; HEATING; HIGH TEMPERATURE; HYDROGEN BOND; INFRARED SPECTROSCOPY; MELTING POINT; RAMAN SPECTROMETRY; SOLID; SURFACE PROPERTY; THERMAL ANALYSIS; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

EID: 67049109390     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21574     Document Type: Article

References (50)

1. Green B. 2004. Focus on aripiprazole. Curr Med Res Opin 20:207-213. (Pubitemid 38197322)
2. Otsuka Pharmaceutical Co. 2003. WO 2003/026659 A1.
3. Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals. 2005. WO 2005/058835 A2.
4. Selection of recent aripiprazole patent applications: (a) Hetero Drugs Limited. 2004. WO 2004/083183 A1.
5. (b) Cadila Healthcare Limited. 2004. WO 2004/106322 A2.
6. (c) Matrix Laboratories Ltd. 2004. IN CH00272 A.
7. (d) Hetero Drugs Limited. 2005. WO 2005/009990 A1.
8. (e) Beijing Dezhong Wangquan Medicine Technology Development Co. 2005. CN 1676517 A.
9. (f) Venkataraman S, Reddy PP, Satyanarayana B, Rangareddy T. 2005. US 2005/277650 A1.
10. (g) Shanghai Institute of Pharmaceutical Industry. 2006. WO 2006/012237 A2.
11. (h) Matrix Laboratories Ltd. 2006.WO2006/030446 A1.
12. (i) Chongqing Pharmaceutical Research Institute Co. 2006. CN 1760183 A.
13. (h) Synthon BV. 2006. WO2006/053780 A1.
14. (j) Chemagis Ltd. 2006.WO2006/077584 A2.
15. (k) Sandoz A-G. 2006. WO 2006/079548 A1.
16. (l) Synthon BV. 2006. WO 2006/097343 A1.
17. (m) Synthon BV. 2006. WO 2006/053780 A1.
18. (n) Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals. 2007. WO2007/041414 A1.
19. (o) Eisen-Nevo H, Pavlov Z. 2007. US 2007/161794 A1.
20. (p) Shanghai Institute of Pharmaceutical Industry. 2007. CN 17727387 A.
21. (q) Chongqing Pharmaceutical Research Institute Co. 2007. CN 1896063 A.
22. Aoki B, Bando T, Kobayashi N. 1996. Study on Crystal Transformation of Aripiprazol [The fourth Japan-Korea Symposium on Separation Technology].
23. Tessler L, Goldberg I. 2006. Crystal structures of aripiprazole, a new anti-psychotic drug, and of its inclusion compounds with methanol, ethanol and water. J Incl Phenom Macro 55:255-261. (Pubitemid 44127263)
24. Medichem SA. 2007. WO 2007/004061A1.
25. a) Bernstein J, Hagler AT. 1978. Conformational polymorphism. The Influence of crystal structure on molecular conformation. J Am Chem Soc 100: 673-681.8.;
26. b) Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Oxford University Press. p 410.
27. Nangia A. 2008. Conformational polymorphism in organic crystals. Acc Chem Res 41:595-604.
28. Griesser UJ, Jetti R, Haddow MF, Brehmer T, Harris RK. 2008. Conformational polymorphism in oxybuprocaine hydrochloride. Cryst Growth Des 8:44-56.
29. Braun DE, Gelbrich T, Kahlenberg V, Laus G, Wieser J, Griesser UJ. Packing polymorphism of a conformationally flexible molecule (aprepitant). New J Chem DOI: 10.1039/b805438j.
30. Braun DE, Gelbrich T, Kahlenberg V, Tessadri R, Wieser J, Griesser UJ. Unpublished results (submitted to Cryst Growth Des).
31. Colthup NB, Daly LH, Wiberley SE. Introduction to infrared and Raman spectroscopy. New York: Academic Press. p 547.
32. Farrugia LJ. 1999. WinGX suite for small-molecule single-crystal crystallography. J Appl Cryst 32:837-838. (Pubitemid 129794704)
33. Altomare A, Burla MC, Camalli M, Cascarano GL, Giacovazzo C, Guagliardi A, Moliterni AGG, Polidori G, Spagna R. 1999. SIR97: A new tool for crystal structure determination and refinement. J Appl Cryst 32:115-119. (Pubitemid 129699322)
34. Sheldrick GM. 2008. A short history of SHELX. Acta Crystallogr A64:112-122.
35. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim Acta 2:259-271.
36. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochim Acta 2:273-316.
37. Grunenberg A, Henck J-O, Siesler HW. 1996. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int J Pharm 129:147-158. (Pubitemid 26097982)
38. Kitaigorodsky AI. 1973. Molecular crystals and molecules. New York, London: Academic Press.
39. Yu L. 1995. Inferring thermodynamic stability relationship of polymorphs from melting data. J Pharm Sci 84:966-974.
40. Griesser UJ, Weigand D, Rollinger JM, Haddow M, Gstrein E. 2004. The crystal polymorphs of metazachlor. J Therm Anal Calorim 77:511-522.
41. Henck J-O. 1995. Konformationspolymorphie n-butylsubstituierter Arzneistoffe. Innsbruck: Thesis, p 41.
42. Bernstein J, Davis RE, Shimoni L, Chang N-L. 1995. Patterns in hydrogen bonding: Functionality and graph set analysis in crystals. Angew Chem Int Ed 34:1555-1573.
43. Etter MC, MacDonald JC, Bernstein J. 1990. Graph-set analysis of hydrogen-bond patterns in organic crystals. Acta Crystallogr B46:256-262.
44. Etter MC. 1990. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc Chem Res 23:120-126.
45. All CSD (version 5.28) searches were performed using Conquest version 1.9 (November 2006, 390081 entries) with the following filters used: 3D coordinates determined, not disordered, R-factor less than 10%, no errors, not polymeric and only organics.
46. Allen F, Shields GP, Taylor R, Raithby PR. 1998. Probabilities of formation of bimolecular cyclic hydrogen-bonded motifs in organic crystal structures: A systematic database analysis. Chem Commun 9:1043-1044. (Pubitemid 128675512)
47. Uno T, Ozeki Y, Koga Y, Chu G-N, Okada M, Tamura K, Igawa T, Unemi F, Kido M, Nishi T. 1995. Synthesis of 2(1H)-quinolinone derivatives and their inhibitory activity on the release of 12(S)-hydroxyeicosatetraenoic acid (12-HETE) from platelets. Chem Pharm Bull 43:1724-1733.
48. McKinnon JJ, Spackman MA, Mitchell AS. 2004. Novel tools for visualizing and exploring intermolecular interactions in molecular crystals. Acta Crystallogr B60:627-668.
49. Wolff SK, Grimwood DJ, McKinnon JJ, Jayatilaka D, Spackman MA. 2007. Crystal Explorer, Version 2.0. University of Western Australia. Australia.
50. Spackman MA, McKinnon JJ. 2002. Fingerprinting intermolecular interactions in molecular crystals. CrystEngComm 4:378-392.